Drug development and commercialisation is all about meeting regulatory requirements, hence clinical trials (end point, mid point, beginning point, any point) and at the end it boils to one thing: data.
AIPAC data will not be the end or all, but is pivotal. IMO, we will survive even with poor AIPAC data. This is because: Efti (or Lag3 related drugs) have shown a strong safety profile and it represents a key aspect of immune system.
And we have patents.
It will happen, next week may well be turning the corner for us, if not, I am patient. We have other trials going, not just AIPAC. We are not a one pony company.
News: IMM Immutep Receives Positive EMA Scientific Advice For Further Clinical Development Of EFTI..., page-19
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
33.0¢ |
Change
-0.010(2.94%) |
Mkt cap ! $480.0M | |||
| Open | High | Low | Value | Volume |
| 33.0¢ | 33.5¢ | 32.0¢ | $1.703M | 5.215M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 211685 | 33.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 33.5¢ | 279000 | 3 |
View Market Depth
| Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
| IMM (ASX) Chart |